However, in MM cells that express wild type (WT) BRAF, dabrafenib and related BRAFi’s are contraindicated because they allosterically stimulate BRAF kinase which leads to hyper-proliferation via the MAPK cascade activation [6, 7]. The gene discussed is BRAF; the disease is Miyoshi myopathy.